Pfizer Inc. $PFE Shares Acquired by Studio Investment Management LLC

Studio Investment Management LLC increased its position in Pfizer Inc. (NYSE:PFE) by 22.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,099 shares of the biopharmaceutical company’s stock after buying an additional 5,595 shares during the quarter. Studio Investment Management LLC’s holdings in Pfizer were worth $730,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of PFE. Brighton Jones LLC lifted its holdings in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Pfizer by 69.0% during the first quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company’s stock valued at $1,600,000 after purchasing an additional 25,785 shares during the last quarter. Flagship Harbor Advisors LLC lifted its holdings in shares of Pfizer by 2.4% during the first quarter. Flagship Harbor Advisors LLC now owns 66,400 shares of the biopharmaceutical company’s stock valued at $1,683,000 after purchasing an additional 1,585 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its holdings in shares of Pfizer by 11.1% during the first quarter. Oppenheimer Asset Management Inc. now owns 323,471 shares of the biopharmaceutical company’s stock valued at $8,197,000 after purchasing an additional 32,203 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on PFE shares. Bank of America upped their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley reduced their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.13.

Pfizer Stock Performance

Shares of PFE stock opened at $24.84 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.17. The stock’s 50-day moving average is $24.89 and its two-hundred day moving average is $24.13. The firm has a market cap of $141.23 billion, a P/E ratio of 13.21, a PEG ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.